Cantor Fitzgerald maintains Overweight on Vaxcyte shares

Cantor Fitzgerald reaffirmed its Overweight rating on Vaxcyte (PCVX), despite a 59% stock decline over six months, citing the strength of the company's pneumococcal conjugate vaccine (PCV) data and the unlikelihood of the upcoming ACIP meeting significantly impacting Vaxcyte's prospects, as its vaccine programs are still years from potential approval. Analyst Carter Gould emphasized the robustness of Vaxcyte's PCV data, supporting the continuation of established immunization strategies, while InvestingPro data indicates a strong analyst consensus with price targets ranging from $65 to $163. The company also recently appointed former Sanofi CEO Dr. Olivier Brandicourt to its Board of Directors.

Analysis

Cantor Fitzgerald has reaffirmed its Overweight rating on Vaxcyte (NASDAQ:PCVX), signaling confidence despite a significant 59% stock price decline over the past six months, although the stock has shown recent resilience with a 7% gain in the past week. This endorsement is partly based on the assessment by Cantor Fitzgerald's analyst Carter Gould that the upcoming Advisory Committee on Immunization Practices (ACIP) meeting is unlikely to materially impact Vaxcyte, as its pneumococcal vaccine programs are still several years from potential approval and subsequent ACIP recommendation. Gould emphasized the robustness of Vaxcyte’s pneumococcal conjugate vaccine (PCV) data, which supports current immunization strategies, particularly considering the historical incidence of invasive pneumococcal disease (IPD). This positive sentiment is reflected in a broader strong bullish analyst consensus, with InvestingPro data indicating price targets for PCVX ranging from $65 to $163. From a financial standpoint, Vaxcyte possesses a strong balance sheet, with cash reserves exceeding debt and a healthy current ratio of 17.7, though the company is not currently profitable. Recent strategic developments bolster the company's outlook, including the appointment of Dr. Olivier Brandicourt, former CEO of Sanofi, to its Board of Directors, a move viewed as enhancing its biopharmaceutical expertise. While Cantor Fitzgerald initiated coverage with an Overweight rating, citing promising VAX-31 adult trial data, and Goldman Sachs maintains a Buy rating, the latter adjusted its price target downwards to $100 from $138 following Phase 2 topline results for VAX-24 in infants that did not meet certain non-inferiority criteria. Despite this specific trial setback, Vaxcyte is actively pursuing strategies to improve VAX-24’s profile and is advancing VAX-31 into a Phase 3 adult clinical program and a Phase 2 infant trial, underscoring its continued commitment to progressing its vaccine pipeline.

Key Decisions for Investors

• Investors should acknowledge Vaxcyte's developmental stage, requiring a long-term investment perspective as its vaccine programs are several years from potential market entry and ACIP recommendation, despite recent stock price fluctuations.
• Key catalysts to monitor include clinical trial readouts for VAX-31 and VAX-24, progress towards regulatory submissions, and any future ACIP discussions relevant to Vaxcyte's candidates, even if the immediate meeting is deemed non-impactful.
• The company's strong cash position relative to debt and positive analyst sentiment offer some support, but the current lack of profitability and specific trial setbacks, such as the VAX-24 infant trial's non-inferiority results, highlight the inherent risks and need for careful due diligence in this biotech investment.